Wellington Shields Capital Management LLC Decreases Stock Position in Edwards Lifesciences Corporation $EW

Wellington Shields Capital Management LLC trimmed its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 10.4% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 49,031 shares of the medical research company’s stock after selling 5,700 shares during the quarter. Wellington Shields Capital Management LLC’s holdings in Edwards Lifesciences were worth $3,835,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. Machina Capital S.A.S. bought a new position in Edwards Lifesciences in the 2nd quarter worth about $3,888,000. Burney Co. purchased a new position in shares of Edwards Lifesciences in the second quarter worth $2,857,000. W.G. Shaheen & Associates DBA Whitney & Co raised its holdings in shares of Edwards Lifesciences by 0.9% in the second quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 168,173 shares of the medical research company’s stock worth $13,153,000 after buying an additional 1,498 shares during the last quarter. Telos Capital Management Inc. increased its stake in shares of Edwards Lifesciences by 12.9% in the second quarter. Telos Capital Management Inc. now owns 62,415 shares of the medical research company’s stock worth $4,881,000 after acquiring an additional 7,156 shares during the period. Finally, Mission Wealth Management LP increased its stake in shares of Edwards Lifesciences by 2.4% in the second quarter. Mission Wealth Management LP now owns 45,530 shares of the medical research company’s stock worth $3,561,000 after acquiring an additional 1,073 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on EW shares. Barclays reiterated an “overweight” rating and issued a $99.00 target price (up previously from $95.00) on shares of Edwards Lifesciences in a research report on Friday. BTIG Research raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research note on Tuesday, July 29th. Argus raised shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Thursday, July 10th. Truist Financial lifted their price target on shares of Edwards Lifesciences from $82.00 to $87.00 and gave the company a “hold” rating in a research report on Tuesday, October 28th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a report on Friday. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $91.24.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $82.48 on Monday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The stock has a market cap of $48.42 billion, a PE ratio of 11.87, a price-to-earnings-growth ratio of 3.97 and a beta of 1.05. The firm’s fifty day simple moving average is $77.58 and its 200-day simple moving average is $76.97. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $87.09.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the firm earned $0.67 earnings per share. Edwards Lifesciences’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.